我要投票 羚锐在中草药行业中的票数:582
· 外 推 电 报 ·
2025-08-20 21:41:42 星期三

【羚锐是哪个国家的品牌?】

羚锐是什么牌子?「羚锐」是 河南羚锐制药股份有限公司 旗下著名品牌。该品牌发源于河南,由创始人熊伟在1999-04-18期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力羚锐品牌出海!将品牌入驻外推网,定制羚锐品牌推广信息,可以显著提高羚锐产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

河南羚锐制药股份有限公司始创于1992年6月,由河南省信阳羚羊山制药厂和香港锐星企业公司合资组建而成,2000年10月成功上市,成长为国内知名制药企业。目前,公司在北京、上海、武汉、郑州、信阳等地控股、参股十余家企业,拥有多个科研、生产基地,其中羚锐新县生态工业园为国内最大的橡胶膏剂药品生产基地,羚锐信阳科技园为国内先进的大型口服药生产基地,建立在北京的羚锐药物研究院和羚锐伟业科技有限公司为公司的科技研发基地。公司资产总额10亿元,年创利税逾亿元,已成为当地经济发展的支柱企业。

公司拥有橡胶膏剂、片剂、胶囊剂、颗粒剂、酊剂等十大剂型百余种产品,其中包括通络祛痛膏(骨质增生一贴灵)、培元通脑胶囊、丹鹿通督片、胃疼宁片、参芪降糖胶囊等独家拥有知识产权的产品及国家中药保护品种和国家医保药品。公司的所有产品剂型及其生产车间均通过国家GMP认证,质量标准实现了与国际接轨。

公司先后被评为“全国中药工业50强企业”、“全国中药系统先进集体”、“全国医药优秀企业”、“国家知识产权试点单位”,1999年和2005年先后两次被中央文明委表彰为“全国精神文明建设工作先进单位”,2001年被国家科技部认定为“国家火炬计划重点高新技术企业”,公司党委被中组部命名表彰为“全国先进基层党组织”;2002年“羚锐”商标被国家工商行政管理总局认定为“中国驰名商标”,成为国内橡胶膏剂药业中首件驰名商标。藉此,羚锐制药被业界誉为“中国橡胶膏剂药业第一品牌”。

浴火淬炼,十数年磨剑,羚锐始崛起,并稳健前进。

以“诚信立业,造福人类”为本,弘“团结、进取、创新、奉献”之志,坚持创新,实施人才兴企战略,以高新技术与传统药理、现代理念与先进文化完美融合,构筑企业平台,共享发展资源,我们将进一步提升核心竞争力,着力打造医药的优秀企业,成就百年基业。

英文翻译:Henan Lingrui Pharmaceutical Co., Ltd. was founded in June 1992 by Henan Xinyang lingyangshan pharmaceutical factory and Hong Kong Ruixing enterprise company. It was successfully listed in October 2000 and grew into a well-known pharmaceutical enterprise in China. At present, the company holds and shares more than ten enterprises in Beijing, Shanghai, Wuhan, Zhengzhou, Xinyang and other places, and has many scientific research and production bases. Among them, Lingrui new County Ecological Industrial Park is the largest rubber paste drug production base in China, Lingrui Xinyang science and technology park is the advanced large oral drug production base in China, and Lingrui Drug Research Institute and Lingrui Weiye science and technology established in Beijing Ltd. is the R & D base of the company. The company has a total assets of 1 billion yuan and an annual income tax of more than 100 million yuan, which has become a pillar enterprise of local economic development. The company has more than 100 kinds of products in ten dosage forms including rubber plaster, tablet, capsule, granule and tincture, including Tongluo Qutong plaster (hyperosteogeny Yitieling), Peiyuan Tongnao capsule, Danlu Tongdu tablet, Weitongning tablet, Shenqi Jiangtang Capsule and other products with exclusive intellectual property rights, national traditional Chinese medicine protection varieties and national medical insurance drugs. All the dosage forms and production workshops of the company have passed the national GMP certification, and the quality standards have been in line with the international standards. The company has been awarded as "top 50 enterprises of Chinese medicine industry", "advanced collective of Chinese medicine system", "excellent enterprise of Chinese medicine" and "pilot unit of national intellectual property". In 1999 and 2005, the company was awarded as "advanced unit of national spiritual civilization construction" by the central civilization Committee. In 2001, the company was recognized as "key high and new technology of national Torch Plan" by the Ministry of science and technology In 2002, "Lingrui" trademark was recognized as "China's well-known trademark" by the State Administration for Industry and commerce, and became the first well-known trademark in the domestic rubber paste pharmaceutical industry. Therefore, Lingrui pharmaceutical is known as "the first brand of Chinese rubber paste pharmaceutical industry". Bath fire quenching, more than ten years of sword sharpening, antelope sharp began to rise, and steady progress. Based on the principle of "building a business in good faith and benefiting mankind", we will carry out the strategy of "uniting, enterprising, innovating and dedicating", persist in innovation, carry out the strategy of developing an enterprise with talents, perfectly integrate high and new technology with traditional pharmacology, modern concept and advanced culture, build an enterprise platform and share development resources. We will further enhance our core competitiveness and strive to build an excellent enterprise in medicine, Achieve a century long foundation.

本文链接: https://www.waitui.com/brand/e8963bc9e.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

江波龙:员工持股平台拟合计减持公司不超1.31%股份

36氪获悉,江波龙公告,龙熹一号、龙熹二号、龙熹三号、龙舰管理、龙熹五号(统称“员工持股平台”)合计持有公司16.53%股份,计划在2025年9月11日至12月10日期间通过集中竞价交易方式和大宗交易方式合计减持公司股份不超过548万股(不超过公司总股本的1.31%)。

2小时前

云南锗业:公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划

36氪获悉,云南锗业发布股票交易异常波动公告,公司了解到,近期有国内研发机构发布了其在6英寸磷化铟外延生长工艺领域实现了技术突破相关事宜。就控股子公司鑫耀公司而言,在2-4英寸规格的磷化铟晶片量产后,为应对未来的市场需求,对更大尺寸的产品开展了研究开发,但从研发到规模化生产尚存在较大不确定性。公司及鑫耀公司目前并无6英寸磷化铟晶片规模化量产的具体计划,下一步在市场与需求风险、技术风险等可控的前提下,公司方会考虑相关计划,如有相关计划,公司会按规定进行公开披露。

2小时前

胜宏科技:向香港联交所递交H股发行并上市申请并刊发申请资料

36氪获悉,胜宏科技公告,公司已于2025年8月20日向香港联交所递交了发行境外上市股份(H股)并在香港联交所主板挂牌上市的申请,并于同日在香港联交所网站刊登了本次发行的申请资料。该申请资料为草拟版本,其所载资料可能会适时作出更新及修订。公司本次发行尚需取得相关政府机关、监管机构、证券交易所的批准、核准或备案。

2小时前

永辉超市:上半年净亏损2.41亿元

36氪获悉,永辉超市公告,公司上半年实现营业总收入299.48亿元,同比下降20.73%;净亏损2.41亿元,上年同期盈利2.75亿元。

2小时前

摩根大通与三菱日联接近达成220亿美元的得州数据中心融资协议

英国《金融时报》周三报道,摩根大通和日本三菱日联金融集团正就为得克萨斯州一个数据中心承销220亿美元贷款展开谈判。报道称,该规划中的园区将由Vantage Data Centers所有,这是一家由银湖资本和资产管理公司DigitalBridge 控股的数字基础设施企业。报道还指出,银湖资本和DigitalBridge将合计承诺30亿美元股权,助力该数据中心园区的建设。(新浪财经)

2小时前

本页详细列出关于羚锐的品牌信息,含品牌所属公司介绍,羚锐所处行业的品牌地位及优势。
咨询